TD Asset Management
DRNA

TD Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

TD Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-74,186
Closed -$1.5M – 1574
2021
Q3 		$1.5M Hold
74,186
– – ﹤0.01% 1160
2021
Q2 		$2.78M Buy
74,186
+18,400
+33% +$564K ﹤0.01% 991
2021
Q1 		$1.43M Sell
55,786
-10,094
-15% -$258K ﹤0.01% 1187
2020
Q4 		$1.45M Hold
65,880
– – ﹤0.01% 1102
2020
Q3 		$1.19M Hold
65,880
– – ﹤0.01% 1056
2020
Q2 		$1.67M Buy
65,880
+1,800
+3% +$38.8K ﹤0.01% 923
2020
Q1 		$1.18M Sell
64,080
-9,200
-13% -$179K ﹤0.01% 957
2019
Q4 		$1.61M Buy
73,280
+18,300
+33% +$368K ﹤0.01% 975
2019
Q3 		$790K Buy
54,980
+1,500
+3% +$21.4K ﹤0.01% 1100
2019
Q2 		$842K Buy
53,480
+16,500
+45% +$224K ﹤0.01% 1083
2019
Q1 		$542K Buy
36,980
+21,180
+134% +$243K ﹤0.01% 1178
2018
Q4 		$169K Buy
+15,800
New +$208K ﹤0.01% 1359

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

TD Asset Management's DRNA Position: Q4 2021 in Review

TD Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 74,186 shares — an estimated $1.5M sold.

TD Asset Management first reported a position in DRNA in Q4 2018 and held it in 12 quarters. The position peaked at $2.78M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • TD Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • TD Asset Management sold 74,186 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.5M.
  • TD Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2018 and held it in 12 quarters.
  • TD Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $2.78M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on TD Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.